January 7, 2014
Reston, Va. – With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in The Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.
Malignant melanoma is the fifth most common cancer in men and the sixth most common cancer in women, and its incidence rate is increasing rapidly. It accounts for nearly 80 percent of all deaths related to cutaneous cancer. When discovered early, localized melanoma can be cured by surgical removal. However, this cancer displays a strong tendency to metastasize and has very low survival rates for patients, with fewer than five percent surviving longer than five years.
In the study “123I-BZA2 as a Melanin-Targeted Radiotracerfor the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial,” researchers developed a specific single photon emission computed tomography (SPECT) radiopharmaceutical for malignant melanoma—123I-BZA2. Imaging of patients with metastasized melanoma was then performed with both 18F-FDG positron emission tomography/computed tomography (PET/CT) and 123I-BZA2 SPECT to compare the accuracy in staging and restaging.
Eighty-seven patients were examined with a total of 86 metastatic lesions. In the analysis of lesions, the sensitivity for 18F-FDG for diagnosis of melanoma metastases was higher than that of 123I-BZA2 (80 percent vs. 23 percent). The specificity of 18F-FDG, however, was lower than 123I-BZA2 (54 percent vs. 86 percent). The sensitivity and specificity of 123I-BZA2 for the diagnosis of melanin-positive lesions were 75 percent and 70 percent, respectively.
“We have demonstrated that 123I-BZA2 tumor accumulation was clearly correlated to melanin content of the melanoma metastases. Thus, 123I -BZA2 could be theoretically used for the diagnosis of melanoma metastases,” said Florent Cachin, MD, PhD, lead author of the study. “However, given its low sensitivity due to the high proportion of non-pigmented lesion in the natural course of metastatic melanoma, 123I- IBZA2 cannot be used for melanoma staging. Such results could appear discouraging, but the concept of melanin targeting may offer a real opportunity for therapy.”
In the study “Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52,” the first use of a melanoma-seeking agent for therapeutic application was analyzed. Researchers used a theranostic approach in which the same molecule was given first as a diagnostic isotope (123I-BA52) to identify the patients possibly profiting from therapy, and then as a therapeutic radiopharmaceutical (131I-BA52) for those patients who would benefit. Twenty-six patients were imaged with 123I-BA52, and nine patients were selected for therapy with 131I-BA52.
Some of the patients treated with 131I-BA52 were found to have a survival rate of more than two years. Researchers also found that higher treatment doses would have been tolerated in these patients, as only moderate side effects were observed. “We believe that the tracer could be useful in the setting of a combination therapy in patients with metastasized melanoma, especially when applied in earlier stages of the disease where the melanin production is higher as compared to later stages of the disease,” noted Uwe Haberkorn, MD, lead author of the study.
Even though new treatments are now available, the prognosis for patients with metastatic melanoma remains very poor. “Innovative strategies are necessary to improve patients’ survival. Research focused on innovating targeted-therapy reflects modern oncology, as new theranostic concepts. This strategy nicely illustrates the future of nuclear medicine oncology,” said Cachin.
Authors of the article “123I-BZA2 as a Melanin-Targeted Radiotracerfor the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial,” include Florent Cachin, Nuclear Medicine, Jean Perrin Cancer Center, Clermont-Ferrand, France, INSERM, UMR 990 IMTV, Clermont Ferrand, France, and Clermont Université, Université d’Auvergne, IMTV, Clermont-Ferrand, France; Elisabeth Miot-Noirault, Jean Michel Chezal and Françoise Degoul, INSERM, UMR 990 IMTV, Clermont Ferrand, France, and Clermont Université, Université d’Auvergne, IMTV, Clermont-Ferrand, France; Brigette Gillet, Dermatology, Estaing University Hospital, Clermont-Ferrand, France; Vanina Isnardi, Nuclear Medicine, University Hospital, Saint-Etienne, France; Bruno Labeille, Dermatology, University Hospital, Saint-Etienne, France; Pierre Payoux, Nuclear Medicine, Purpan University Hospital, Toulouse, France; Nicolas Meyer, Dermatology, Larrey University Hospital, Toulouse, France; Serge Cammilleri, Nuclear Medicine, La Timone University Hospital, Marseille, France; Caroline Gaudy, Dermatology, La Timone University Hospital, Marseille, France; Micheline Razzouk-Cadet, Nuclear Medicine, Archet University Hospital, Nice, France; Jean Phillipe Lacour, Dermatology, Archet University Hospital, Nice, France; Florence Granel-Brocard, Dermatology, Brabois University Hospital, Nancy, France; Christelle Tychyj, Nuclear Medicine, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France; Fathalah Benbouzid and Jean Daniel Grange, Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France; Françoise Baulieu, Nuclear Medicine, Trousseau University Hospital, Tours, France; Antony Kelly, Charles Merlin and Daniel Mestas, Nuclear Medicine, Jean Perrin Cancer Center, Clermont-Ferrand, France; Françoise Gachon, Radiopharmacy, Jean Perrin Cancer Center, Clermont-Ferrand, France; and Michel D’Incan, INSERM, UMR 990 IMTV, Clermont Ferrand, France, Clermont Université, Université d’Auvergne, IMTV, Clermont-Ferrand, France, and Dermatology, Estaing University Hospital, Clermont-Ferrand, France.
Authors of the article “Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52” include Walter Mier, Clemens Kratochwil, Frederik L. Giesel, Barbro Beijer, and Uwe Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; Jessica C. Hassel and Alexander Enk, Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; John W. Babich, Molecular Insight Pharmaceuticals, Cambridge, Massachusetts; Matthias Friebe, Bayer Pharma AG, Research Laboratories, Berlin, Germany; and Michael Eisenhut, Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Susan Martonik at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.